No question that the marketing people at Sanofi were excited about alirocumab, the next-generation cholesterol drug that won approval earlier this year. Analysts had been talking about multibillion-dollar sales, and recent trial data--not just from Sanofi and its partner Regeneron--built optimism even further.
Regeneron Pharmaceuticals, riding high with a top-selling eye drug and some promising pipeline assets, is planning to invest $150 million in its native New York, supporting 300 new jobs at its fast-growing R&D campus.
Rapidly expanding Eylea-maker Regeneron Thursday announced that it will invest another $150 million to grow its Tarrytown, NY, campus with plans to add another 300 jobs, The Journal News reports.
All the hullabaloo over pharma's drug-pricing practices has taken its toll on several of the industry's stocks. But not Gilead Sciences and Regeneron: While both sank in September on Hillary Clinton's announcement that she'd be cracking down on "price-gouging," they've climbed their way back up.
A couple of years ago, U.S.-based Regeneron said it would turn a former Dell computer plant in Ireland into its production operation outside of the U.S. But with the company booming, what started as a $300 million project needing 300 workers has morphed into a $650 million project that will require 500.
Regeneron says it will more than double its investment and hire an additional 200 workers at a plant still under construction in Ireland. That comes even as it is adding space to its campus in Tarrytown, NY, where it expects its headcount this year to grow by 1,000.
Regeneron is handing off the Asian rights to its in-development musculoskeletal pain treatment for up to $325 million, handing the antibody over to a subsidiary of Japanese giant Mitsubishi.
Payers unhappy with the cost of new PCSK9 drugs are getting some ammo, as top U.S. physicians are recommending against using the drugs in a large patient pool.
Back at the beginning of 2014, a fast-growing Regeneron revealed that it had been building a new genetics research center that would zero in on carefully targeted diseases as it built new drug development programs from the ground up. Eighteen months later the big biotech says the effort--led by some top researchers wooed in to run the operation--has paid off with a clear target for a rare genetic bone disease. And they have an antibody in preclinical testing that could correct the disorder.
Boosted by a major new drug approval, a booming Regeneron Pharmaceuticals is swelling rapidly in size. The big biotech has added 116,200 square feet of office/lab space to its lease at the Landmark at Eastview research campus in Tarrytown, NY, about 30 minutes from Manhattan. The expansion swells Regeneron's footprint on the campus to a giant-sized 1.1 million square feet, according to landlord BioMed Realty Trust.